AREDS2 Vitamins for Macular Degeneration: What the Research Really Shows
Written by Dr. Louis Michaelos, Ophthalmologist & Founder, MacuRest | Last reviewed May 2026
The AREDS2 study, sponsored by the National Eye Institute and published in 2013, enrolled 4,203 participants and found a specific six-nutrient combination reduced AMD progression to advanced stages by approximately 25% over five years. Here is what it actually proved — and what it didn't.
What the AREDS2 Study Actually Proved
The Age-Related Eye Disease Study 2 is one of the most important nutritional intervention trials ever conducted for any eye condition. Sponsored by the National Eye Institute and published in JAMA in 2013, AREDS2 enrolled 4,203 participants with intermediate or advanced AMD in one eye and followed them for an average of five years. The core finding: a specific combination of nutrients reduced the risk of AMD progressing to an advanced stage by approximately 25%. Full results: PubMed (PMCID: PMC3820261).
The Six Nutrients That Were Tested
- Lutein — 10mg: Concentrates in the macular pigment and filters blue light.
- Zeaxanthin — 2mg: Paired with lutein in the central macula where vision is sharpest.
- Vitamin C — 500mg: Protects retinal and lens tissue from oxidative stress.
- Vitamin E — 400 IU: Protects phospholipid membranes of retinal cells.
- Zinc — 80mg: Essential for vitamin A metabolism in the RPE.
- Copper — 2mg: Offsets the copper-depleting effect of high-dose zinc.
What Changed from the Original AREDS Formula
The original AREDS study used beta-carotene instead of lutein and zeaxanthin. AREDS2 replaced it because beta-carotene increases lung cancer risk in smokers. Read: AREDS vs AREDS2 — what changed?
Who the Formula Is For
The American Academy of Ophthalmology recommends AREDS2 for people with intermediate AMD or advanced AMD in one eye. Not for early AMD or no AMD.
What the Formula Does Not Do
The AREDS2 formula slows progression. It does not restore lost vision, prevent AMD onset, or replace anti-VEGF treatment for wet AMD. And it does not address the overnight repair cycle. Emerging research on melatonin and eye health suggests combining AREDS2 with melatonin in the evening may support this critical window. MacuRest delivers the full AREDS2-inspired formula plus melatonin for evening use.
Related: Why a multivitamin isn't enough | How long do eye vitamins take to work?
Frequently Asked Questions
What did the AREDS2 study prove?
The National Eye Institute's AREDS2 trial enrolled 4,203 participants with intermediate or advanced AMD and found a specific six-nutrient formula — lutein 10mg, zeaxanthin 2mg, vitamins C and E, zinc 80mg, copper 2mg — reduced AMD progression to advanced stages by approximately 25% over five years. This is the clinical foundation for AREDS2 supplementation.
How many people were in the AREDS2 study?
4,203 participants with intermediate or advanced AMD in one eye, followed for an average of five years. The study was sponsored by the National Eye Institute (NIH) and published in JAMA in 2013.
Does AREDS2 work for both dry and wet AMD?
The AREDS2 formula is recommended for patients with intermediate AMD (typically dry) or advanced AMD in one eye to protect the fellow eye. For active wet AMD, anti-VEGF injections are the primary treatment. AREDS2 supplementation is typically continued alongside anti-VEGF therapy to protect the second eye.
Can AREDS2 vitamins prevent macular degeneration?
The AREDS2 trial was not designed to prevent AMD onset — it was designed to slow progression in people who already had intermediate or advanced AMD. It did not show statistically significant benefit for people with early AMD or no AMD. The AAO recommends it specifically for the intermediate/advanced AMD population.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.